Pharmacokinetics and clinical efficacy of pioglitazone

International Journal of Clinical Practice, Supplement

Volumn , Issue 121, 2001, Pages 19-25

  Hanefeld, M ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PIOGLITAZONE; PLACEBO; SULFONYLUREA; THIAZOLIDINE DERIVATIVE;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG STRUCTURE; ENANTIOMER; HUMAN; LIVER FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPOGLYCEMIC AGENTS; RISK FACTORS; THIAZOLES; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 0034810107     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. Clinical pharmacokinetics of pioglitazone
2. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: Comparison with pioglitazone and rosiglitazone
3. Pharmacokinetics of pioglitazone in patients with renal impairment
4. Pioglitazone has low potential for drug interactions
5. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study
6. Effect of pioglitazone on blood glucose following an oral glucose challenge
7. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49)
8. Combination therapy with pioglitazone and sulfonylurea in patients with type 2 diabetes
9. Combining pioglitazone with a sulphonylurea or metformin in the management of type 2 diabetes
10. Dose finding study of AD-4833 in NIDDM patients on treatment with a sulphonylurea drug
11. Clinical evaluation of an insulin resistance improving agent, AD-4833, in patients with non-insulin dependant diabetes mellitus (NIDDM) on treatment with an SU drug
12. Improved insulin sensitivity and beta cell responsivity suggested by HOMA analysis of pioglitazone therapy
13. Pioglitazone hydrochloride in combination with metformin in the treatment of patients with type 2 diabetes mellitus: A randomized placebo-controlled study
14. Combination therapy with pioglitazone and insulin in patients with type 2 diabetes
15. Cardiovascular mortality and morbidity in Type-2 diabetes mellitus
16. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial
17. Insulin resistance - How important is it to treat?
18. The effect of pioglitazone on the lipid profile in patients with type 2 diabetes
19. The effect of combination therapy with pioglitazone and sulfonylurea on the lipid profile in patients with type 2 diabetes
20. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones
21. Pioglitazone reduces dense LDL particles in patients with type 2 diabetes